PortfoliosLab logoPortfoliosLab logo
AMLX vs. NUTX
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Performance

AMLX vs. NUTX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Amylyx Pharmaceuticals, Inc. (AMLX) and Nutex Health Inc (NUTX). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

AMLX vs. NUTX - Yearly Performance Comparison


2026 (YTD)2025202420232022
AMLX
Amylyx Pharmaceuticals, Inc.
15.07%219.58%-74.32%-60.16%165.83%
NUTX
Nutex Health Inc
-42.27%419.47%17.37%-90.53%-95.25%

Fundamentals

EPS

AMLX:

-$1.57

NUTX:

$14.78

Total Revenue (TTM)

AMLX:

$0.00

NUTX:

$875.26M

Gross Profit (TTM)

AMLX:

$0.00

NUTX:

$444.28M

EBITDA (TTM)

AMLX:

-$144.16M

NUTX:

$274.31M

Returns By Period

In the year-to-date period, AMLX achieves a 15.07% return, which is significantly higher than NUTX's -42.27% return.


AMLX

1D
8.93%
1M
-8.37%
YTD
15.07%
6M
2.28%
1Y
292.66%
3Y*
-22.04%
5Y*
10Y*

NUTX

1D
4.55%
1M
-13.96%
YTD
-42.27%
6M
-8.01%
1Y
102.08%
3Y*
-14.40%
5Y*
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

AMLX vs. NUTX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

AMLX
AMLX Risk / Return Rank: 9797
Overall Rank
AMLX Sharpe Ratio Rank: 9999
Sharpe Ratio Rank
AMLX Sortino Ratio Rank: 9797
Sortino Ratio Rank
AMLX Omega Ratio Rank: 9494
Omega Ratio Rank
AMLX Calmar Ratio Rank: 9898
Calmar Ratio Rank
AMLX Martin Ratio Rank: 9898
Martin Ratio Rank

NUTX
NUTX Risk / Return Rank: 7272
Overall Rank
NUTX Sharpe Ratio Rank: 7272
Sharpe Ratio Rank
NUTX Sortino Ratio Rank: 7979
Sortino Ratio Rank
NUTX Omega Ratio Rank: 7474
Omega Ratio Rank
NUTX Calmar Ratio Rank: 7272
Calmar Ratio Rank
NUTX Martin Ratio Rank: 6464
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

AMLX vs. NUTX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Amylyx Pharmaceuticals, Inc. (AMLX) and Nutex Health Inc (NUTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


AMLXNUTXDifference

Sharpe ratio

Return per unit of total volatility

4.03

0.88

+3.15

Sortino ratio

Return per unit of downside risk

4.16

1.99

+2.17

Omega ratio

Gain probability vs. loss probability

1.49

1.24

+0.25

Calmar ratio

Return relative to maximum drawdown

10.02

1.54

+8.47

Martin ratio

Return relative to average drawdown

23.29

2.40

+20.89

AMLX vs. NUTX - Sharpe Ratio Comparison

The current AMLX Sharpe Ratio is 4.03, which is higher than the NUTX Sharpe Ratio of 0.88. The chart below compares the historical Sharpe Ratios of AMLX and NUTX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading graphics...

Sharpe Ratios by Period


AMLXNUTXDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

4.03

0.88

+3.15

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.07

-0.48

+0.41

Correlation

The correlation between AMLX and NUTX is 0.16, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Dividends

AMLX vs. NUTX - Dividend Comparison

Neither AMLX nor NUTX has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

AMLX vs. NUTX - Drawdown Comparison

The maximum AMLX drawdown since its inception was -96.04%, roughly equal to the maximum NUTX drawdown of -99.93%. Use the drawdown chart below to compare losses from any high point for AMLX and NUTX.


Loading graphics...

Drawdown Indicators


AMLXNUTXDifference

Max Drawdown

Largest peak-to-trough decline

-96.04%

-99.93%

+3.89%

Max Drawdown (1Y)

Largest decline over 1 year

-27.93%

-54.34%

+26.41%

Current Drawdown

Current decline from peak

-66.04%

-98.42%

+32.38%

Average Drawdown

Average peak-to-trough decline

-59.24%

-97.24%

+38.00%

Ulcer Index

Depth and duration of drawdowns from previous peaks

12.01%

34.90%

-22.89%

Volatility

AMLX vs. NUTX - Volatility Comparison

The current volatility for Amylyx Pharmaceuticals, Inc. (AMLX) is 19.23%, while Nutex Health Inc (NUTX) has a volatility of 24.94%. This indicates that AMLX experiences smaller price fluctuations and is considered to be less risky than NUTX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading graphics...

Volatility by Period


AMLXNUTXDifference

Volatility (1M)

Calculated over the trailing 1-month period

19.23%

24.94%

-5.71%

Volatility (6M)

Calculated over the trailing 6-month period

45.20%

73.87%

-28.67%

Volatility (1Y)

Calculated over the trailing 1-year period

73.18%

116.41%

-43.23%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

92.82%

135.16%

-42.34%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

92.82%

135.16%

-42.34%

Financials

AMLX vs. NUTX - Financials Comparison

This section allows you to compare key financial metrics between Amylyx Pharmaceuticals, Inc. and Nutex Health Inc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0050.00M100.00M150.00M200.00M250.00MAprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober0
151.68M
(AMLX) Total Revenue
(NUTX) Total Revenue
Values in USD except per share items